Page 48 - GALENIKA MEDICAL JOURNAL

outperformed placebo, but the mechanisms behind their benefits remain unclear. Prioritizing cardiovascular safety and
preventing complications is essential for patients with T2DM when selecting a treatment.

Keywords: GLP-1 analogues, diabetes mellitus, cardiovascular diseases

Literatura 13. Jung HW, Ra M, Bae HJ, Hong SP. The LDL-C/Apo B predicts coronary
atherosclerotic heart disease in non-diabetic patients without high
LDL-C. Medicine (Baltimore). 2023 Jan 6; 102(1):e32596.
1. Søndergaard E, Nielsen S. VLDL triglyceride accumulation in skeletal 14. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro
muscle and adipose tissue in type 2 diabetes. Curr Opin Lipidol. 2018 MD, Moriarty PM, et al. Apolipoprotein C-III reduction in subjects with
Feb; 29(1):42–7. moderate hypertriglyceridaemia and at high cardiovascular risk. Eur
2. Schnell O, Rydén L, Standl E, Ceriello A. Current perspectives on Heart J. 2022 Jan 13; 43(14):1401-12.
cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2016 15. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, et al.
Oct 1; 15:139. Exenatide twice daily versus glimepiride for prevention of glycaemic
3. Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et deterioration in patients with type 2 diabetes with metformin failure
al. Diabetes mellitus: Classification, mediators, and complications; A (EUREXA): an open-label, randomised controlled trial. Lancet. 2012 Jun
gate to identify potential targets for the development of new effective 16; 379(9833):2270-8.
treatments. Biomed Pharmacother. 2023 Dec; 168:115734. 16. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects
4. Pipke R, Amrhein N, Jacob GS, Schaefer J, Kishore GM. Metabolism of of exenatide (exendin-4) on glycemic control and weight over 30 weeks
glyphosate in an Arthrobacter sp. GLP-1. Eur J Biochem. 1987 Jun 1; in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005
165(2):267-73. May; 28(5):1092-100.
5. Yu W, Zha W, Ren J. Exendin-4 and Liraglutide Attenuate Glucose 17. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et
Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary
Autophagy. Oxid Med Cell Longev. 2018 Apr 19; 2018:5396806. Syndrome. N Engl J Med. 2015 Dec 3; 373(23):2247-57.
6. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, et al. Interim 18. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al.
analysis of the effects of exenatide treatment on A1C, weight and Effects of glucagon-like peptide-1 in patients with acute myocardial
cardiovascular risk factors over 82 weeks in 314 overweight patients infarction and left ventricular dysfunction after successful reperfusion.
with type 2 diabetes. Diabetes Obes Metab. 2006 Jul; 8(4):436-47. Circulation. 2004 Mar 2; 109(8):962-5.
7. Chalmers J, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, 19. Lønborg J, Vejlstrup N, Kelbæk H, Bøtker HE, Kim WY, Mathiasen AB, et
et al. Effects of combination of perindopril, indapamide, and calcium al. Exenatide reduces reperfusion injury in patients with ST-segment
channel blockers in patients with type 2 diabetes mellitus: results from elevation myocardial infarction. Eur Heart J. 2012 Jun; 33(12):1491-9.
the Action In Diabetes and Vascular Disease: Preterax and Diamicron 20. Chen WR, Chen YD, Tian F, Yang N, Cheng LQ, Hu SY, et al. Effects
Controlled Evaluation (ADVANCE) trial. Hypertension. 2014 Feb; of Liraglutide on Reperfusion Injury in Patients With ST-Segment-
63(2):259-64. Elevation Myocardial Infarction. Circ Cardiovasc Imaging. 2016 Dec;
8. Jain AB, Kanters S, Khurana R, Kissock J, Severin N, Stafford SG. 9(12):e005146.
Real-World Effectiveness Analysis of Switching From Liraglutide or 21. Berndt J, Ooi SL, Pak SC. What Is the Mechanism Driving the Reduction
Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: of Cardiovascular Events from Glucagon-like Peptide-1 Receptor
The Retrospective REALISE-DM Study. Diabetes Ther. 2021 Feb; Agonists?-A Mini Review. Molecules. 2021 Aug 10; 26(16):4822.
12(2):527-36.
9. Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 Receptor Agonists and
Cardiovascular Disease in Patients with Type 2 Diabetes. J Diabetes Res. Konflikt interesa: Nema
2018; 2018:4020492.
Primljeno: 02. 08. 2024.
10. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et
al. Association of systolic blood pressure with macrovascular and Prihvaćeno: 20. 09. 2024.
microvascular complications of type 2 diabetes (UKPDS 36): prospective Onlajn: 31. 12. 2024.
observational study. BMJ. 2000 Aug 12; 321(7258):412-9.
11. McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM,
Blumenthal RS, et al. Diastolic blood pressure, subclinical myocardial
damage, and cardiac events: Implications for blood pressure control. J
Am Coll Cardiol. 2016 Oct 18; 68(16):1713-22.
12. Uzoigwe C, Liang Y, Whitmire S, Paprocki Y. Semaglutide Once-Weekly
Persistence and Adherence Versus Other GLP-1 RAs in Patients with
Type 2 Diabetes in a US Real-World Setting. Diabetes Ther. 2021 May;
12(5):1475-89.

46 DOI: 10.5937/Galmed2412038C